433 related articles for article (PubMed ID: 30959004)
1. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
[TBL] [Abstract][Full Text] [Related]
2. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
3. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study.
Abraham JR; Wykoff CC; Arepalli S; Lunasco L; Yu HJ; Hu M; Reese J; Srivastava SK; Brown DM; Ehlers JP
Am J Ophthalmol; 2021 Feb; 222():328-339. PubMed ID: 32896498
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema.
Imazeki M; Noma H; Yasuda K; Motohashi R; Goto H; Shimura M
Ophthalmic Res; 2021; 64(1):43-49. PubMed ID: 32454504
[TBL] [Abstract][Full Text] [Related]
5. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema.
Shimura M; Yasuda K; Motohashi R; Kotake O; Noma H
Br J Ophthalmol; 2017 Nov; 101(11):1518-1523. PubMed ID: 28270488
[TBL] [Abstract][Full Text] [Related]
6. Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.
Podkowinski D; Orlowski-Wimmer E; Zlabinger G; Pollreisz A; Mursch-Edlmayr AS; Mariacher S; Ring M; Bolz M
Acta Ophthalmol; 2020 Jun; 98(4):e407-e415. PubMed ID: 31736269
[TBL] [Abstract][Full Text] [Related]
7. Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema.
Yu SY; Nam DH; Lee DY
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):39-47. PubMed ID: 29030692
[TBL] [Abstract][Full Text] [Related]
8. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
James DGP; Mitkute D; Porter G; Vayalambrone D
Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
10. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
[TBL] [Abstract][Full Text] [Related]
11. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
12. ASSOCIATION OF SERUM VASOGENIC AND PROINFLAMMATORY FACTORS WITH CLINICAL RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR DIABETIC MACULAR EDEMA.
Brito PS; Costa JV; Barbosa-Matos C; Costa SM; Correia-Pinto J; Silva RM
Retina; 2021 Feb; 41(2):345-354. PubMed ID: 32453069
[TBL] [Abstract][Full Text] [Related]
13. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
14. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
16. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
[TBL] [Abstract][Full Text] [Related]
17. Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema.
Shiraya T; Kato S; Araki F; Ueta T; Miyaji T; Yamaguchi T
PLoS One; 2017; 12(3):e0174340. PubMed ID: 28346545
[TBL] [Abstract][Full Text] [Related]
18. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
19. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
[TBL] [Abstract][Full Text] [Related]
20. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
